Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.68 |
| ▸ | HRH2 | P25021 | 10/20 | 0.68 |
| ▸ | HRH1 | P35367 | 10/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714467 | 0.94 | HRH3 (0.68) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| SCHEMBL3562862 | 0.92 | HRH3 (0.62) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| SCHEMBL3560997 | 0.92 | HRH3 (0.66) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| Water SCHEMBL2903086 | 0.92 | HRH3 (0.66) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| SCHEMBL1714617 | 0.89 | HRH3 (0.61) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| SCHEMBL2899427 | 0.89 | HRH3 (0.58) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| SCHEMBL3559203 | 0.88 | SIGMAR1 (0.56) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| SCHEMBL3558558 | 0.88 | SIGMAR1 (0.56) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| SCHEMBL7328846 | 0.86 | HRH3 (0.61) | HRH3HRH2HRH1SIGMAR1MEN1 | |
| SCHEMBL1715391 | 0.85 | HRH3 (0.84) | HRH3HRH2HRH1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993603-B2 | Pharmaceutical composition and method using antifungal agent in combination | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-8993603-B2 | Pharmaceutical composition and method using antifungal agent in combination | TOYAMA CHEMICAL CO., LTD. (JP) | 2015-03-31 | — | — | US | disclosed |
| JP-5314284-B2 | — | — | 2013-10-16 | — | — | JP | disclosed |
| US-8536343-B2 | Arylamidine derivative, salt thereof and antifungal agent containing those | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-8536343-B2 | Arylamidine derivative, salt thereof and antifungal agent containing those | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| EP-1767526-B1 | ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO LTD (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-1867332-B1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO LTD (JP) | 2011-08-24 | — | — | EP | disclosed |
| EP-1967190-B1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO LTD (JP) | 2010-08-04 | — | — | EP | disclosed |
| US-7700623-B2 | Arylamidine derivative, salt thereof, and antifungal containing these | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-7700623-B2 | Arylamidine derivative, salt thereof, and antifungal containing these | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1967190-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-09-10 | — | — | EP | disclosed |
| EP-1867332-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007055197-A1 | METHOD FOR PRODUCING 4-(3-(4-(3-(4-CYANOPHENOXY)PROPYL)- 1-PIPERIDINYL)PROPOXY)BENZONITRILE AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007055197-A1 | METHOD FOR PRODUCING 4-(3-(4-(3-(4-CYANOPHENOXY)PROPYL)- 1-PIPERIDINYL)PROPOXY)BENZONITRILE AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-05-18 | — | — | WO | disclosed |
| EP-1767526-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF, AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-1767526-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF, AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087480-A1 | PHARMACEUTICAL COMPOSITION AND METHOD USING ANTIFUNGAL AGENT IN COMBINATION | PIK3C3, ARSA, ACR | HRH3 7/4885HRH2 8/4885HRH1 14/4885 |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | NAT1, ERG28, SLC7A1 | HRH3 78/4885HRH2 251/4885HRH1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.